Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
31
NTLA Quote, Financials, Valuation and Earnings
Last price:
$10.13
Seasonality move
:
-0.83%
Day range:
$9.31 - $10.17
52-week range:
$5.90 - $28.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.73x
P/B ratio:
1.51x
Volume:
4.3M
Avg. volume:
3.7M
1-year change:
-23.98%
Market cap:
$1.1B
Revenue:
$57.9M
EPS (TTM):
-$4.27
Analysts' Opinion
-
Consensus RatingIntellia Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 11 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $22.34, Intellia Therapeutics, Inc. has an estimated upside of 129.61% from its current price of $9.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 58.89% downside risk from its current price of $9.73.
Fair Value
-
According to the consensus of 22 analysts, Intellia Therapeutics, Inc. has 129.61% upside to fair value with a price target of $22.34 per share.
NTLA vs. S&P 500
-
Over the past 5 trading days, Intellia Therapeutics, Inc. has overperformed the S&P 500 by 4.93% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Intellia Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intellia Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Intellia Therapeutics, Inc. reported revenues of $13.8M.
Earnings Growth
-
Intellia Therapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Intellia Therapeutics, Inc. reported earnings per share of -$0.92.
Enterprise value:
713.9M
EV / Invested capital:
--
Price / LTM sales:
17.73x
EV / EBIT:
--
EV / Revenue:
12.41x
PEG ratio (5yr expected):
-1.19x
EV / Free cash flow:
-1.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$45M
Return On Assets:
-43.08%
Net Income Margin (TTM):
-774.94%
Return On Equity:
-54.66%
Return On Invested Capital:
-47.33%
Operating Margin:
-808.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $51.8M | $43.1M | $57.5M | $9.1M | $13.8M | |
| Gross Profit | $43.2M | $32.9M | $45M | $6.5M | $8.8M | |
| Operating Income | -$485.5M | -$537.7M | -$472.2M | -$144.8M | -$111.5M | |
| EBITDA | -$476.9M | -$527.5M | -$459.7M | -$142.2M | -$106.5M | |
| Diluted EPS | -$5.35 | -$5.45 | -$4.27 | -$1.34 | -$0.92 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $814.8M | $858.9M | $893.5M | $710.9M | $581.9M | |
| Total Assets | $1.3B | $1.1B | $1.2B | $1.2B | $925.3M | |
| Current Liabilities | $97.6M | $131.1M | $92M | $105.7M | $93.7M | |
| Total Liabilities | $227.9M | $259.5M | $205.9M | $210.7M | $176.9M | |
| Total Equity | $1.1B | $825M | $1B | $962.6M | $748.4M | |
| Total Debt | $67.3M | $84.1M | $101.3M | $82.4M | $70.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$390.9M | -$356.7M | -$410.6M | -$84.8M | -$76.9M | |
| Cash From Investing | -$107.4M | $19.9M | $352.1M | -$7.7M | -$741K | |
| Cash From Financing | $529.6M | $289.9M | $131.8M | $82.2M | $114.9M | |
| Free Cash Flow | -$407.3M | -$363.1M | -$412.6M | -$86.1M | -$76.9M | |
NTLA
Sector
Market Cap
$1.1B
$28.5M
Price % of 52-Week High
34.44%
51.36%
Dividend Yield
0%
0%
Shareholder Yield
-6.51%
-1.55%
1-Year Price Total Return
-23.98%
-20%
Beta (5-Year)
2.054
0.497
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.34
200-day SMA
Sell
Level
$11.33
Bollinger Bands (100)
Sell
Level
7.82 - 18.86
Chaikin Money Flow
Sell
Level
-127.7M
20-day SMA
Buy
Level
$9.29
Relative Strength Index (RSI14)
Buy
Level
51.16
ADX Line
Buy
Level
13.5
Williams %R
Neutral
Level
-30.7692
50-day SMA
Sell
Level
$10.46
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.221)
Sell
CA Score
(Annual)
Level (-1.1349)
Buy
Beneish M-Score
(Annual)
Level (-3.4644)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.437)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, NTLA has received 10 Buy ratings 11 Hold ratings, and 1 Sell ratings. The NTLA average analyst price target in the past 3 months is $22.34.
-
Where Will Intellia Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intellia Therapeutics, Inc. share price will rise to $22.34 per share over the next 12 months.
-
What Do Analysts Say About Intellia Therapeutics, Inc.?
Analysts are divided on their view about Intellia Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intellia Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Intellia Therapeutics, Inc.'s Price Target?
The price target for Intellia Therapeutics, Inc. over the next 1-year time period is forecast to be $22.34 according to 22 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is NTLA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intellia Therapeutics, Inc. is a Hold. 11 of 22 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NTLA?
You can purchase shares of Intellia Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intellia Therapeutics, Inc. shares.
-
What Is The Intellia Therapeutics, Inc. Share Price Today?
Intellia Therapeutics, Inc. was last trading at $10.13 per share. This represents the most recent stock quote for Intellia Therapeutics, Inc.. Yesterday, Intellia Therapeutics, Inc. closed at $9.73 per share.
-
How To Buy Intellia Therapeutics, Inc. Stock Online?
In order to purchase Intellia Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NTLA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NTLA
Sector
P/E ratio
--
24.20x
PEG ratio
-1.19x
-0.01x
P/B ratio
1.51x
1.84x
Price / LTM sales
17.73x
1.60x
Growth Metrics
NTLA
Sector
Revenue growth
51.27%
4.62%
Earnings growth
31.56%
10.88%
Revenue (5-year growth)
6.07%
6.45%
Earnings forecast
-$0.97
-$0.18
Profitability
NTLA
Sector
Profitability FY 2024
$47.6M
$3.6M
Return on invested capital
-47.33%
-32.02%
Return on assets
-43.08%
-28.31%
Return on equity
-54.66%
-38%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
NTLA
Sector
Total cash
$511M
$26.1M
Short term investments
$412.3M
$25.7M
Total assets
$1.2B
$76.6M
Long term debt
$70.6M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
